Fixed Drug Eruption after ChAdOx1 nCoV-19 Vaccine

Introduction: ChAdOx1 nCoV-19 vaccine is an adenoviral-vectored COVID-19 vaccine. The most common side effects are headache, muscle pain, redness, swelling, and tenderness at the injection site. Cutaneous reactions have been rarely reported. Objective: To discuss the association between a fixed drug eruption (FDE) and ChAdOx1 nCoV-19 vaccine. Methods: We report one case of (FDE) following administration of the ChAdOx1 nCoV-19. Results: A 60-year-old man with no medical history and no regular medication presented with a rash that had appeared 24 hours after he had received his first dose of the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca). The lesions had appeared abruptly without any accompanying symptoms. Physical examination revealed three, well-defined, round to oval, erythematous to violaceous plaques in the face. A punch biopsy was taken, and histopathology findings were consistent with fixed drug eruption. Conclusion: This case shows that the fixed drug eruption can be a result of receiving the ChAdOx1 nCoV-19 vaccine (OxfordAstraZeneca).